Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
489 active trials5 approved drugs31 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,380 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy | withdrawn | Phase 4 | 0 | Yonsei UniversityOTHER | 0 | Jan 29, 2019 |
| clinicaltrials |
| NCT02496832 | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo | withdrawn | N/A | 0 | University Health Network, TorontoOTHER | 0 | Feb 19, 2018 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT01784081 | Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer(iPC3) | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 10, 2016 | clinicaltrials |
| NCT01911416 | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer | withdrawn | N/A | 0 | University of UtahOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01814631 | Endoscopic Ultrasound (EUS) Processor Comparison | withdrawn | — | 0 | AdventHealthOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 28, 2015 | clinicaltrials |
| NCT02310971 | Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas | withdrawn | Phase 2 | 0 | Prima BioMed LtdINDUSTRY | 0 | Apr 3, 2015 | clinicaltrials |
| NCT01741597 | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | May 30, 2014 | clinicaltrials |
| NCT01830322 | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01401387 | Pancreatic Enzyme Suppletion in Pancreatic Cancer(EPC) | withdrawn | Phase 4 | 0 | Foundation for Liver ResearchOTHER | 1 | Feb 22, 2013 | clinicaltrials |
Data updated 22 days agoSource updated May 30, 2019source: clinicaltrials